Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and T
about
Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasiaCan we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.[Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].[Benign prostatic hyperplasia and urolithiasis].5-α reductase inhibitors and prostate cancer prevention: where do we turn now?Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year rExperience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasiaEvidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.itAction Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia.Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto.Dutasteride/tamsulosin: in benign prostatic hyperplasia.Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.Current pharmacological treatment options for male lower urinary tract symptoms.Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.Medical management of benign prostatic hyperplasia: Results from a population-based study.Trends in Simple Prostatectomy for Benign Prostatic Hyperplasia.Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?Antrodan, a β-glucan obtained from Antrodia cinnamomea mycelia, is beneficial to benign prostate hyperplasia.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manageActual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.[Combination therapy of benign prostate syndrome/lower urinary tract symptoms].How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong
P2860
Q26770425-B9BCF867-E053-4EDE-A6C8-81512DBAA183Q31110115-1BEA30BB-EBA1-43B0-AF6B-768A764467B1Q31149371-CAF65191-4087-438A-BCCE-8898D825C674Q33991602-3F59D434-0D27-4D7D-A6A6-8ECDD71BEFB1Q34020127-119CEF6D-5FC5-4C1F-B7D1-6A9C63DE0E41Q34294888-90DE7DB8-18DD-47D6-A138-F2C0588D44CDQ34377799-2A949DB5-42BE-47FE-99E2-F5EDBA955882Q34643351-98ED9770-6E99-4B0A-9F6D-C8C893C45038Q36379355-2AADAA24-3B35-43A8-B470-5CE1994DD68FQ36838223-52A38B34-1B54-40FB-A7CD-450B31F499D9Q37523940-43AEE06F-3EC0-4017-992F-147DC63F7ED4Q38006977-7136FF05-5594-43C3-8B77-3B7E07449983Q38098896-2E9BDACE-5DA8-4794-845D-4F07742BF477Q38103891-18189D39-77FD-4F75-8D7F-8F5CC542B095Q38210468-CD04B98B-7A54-4D31-AC44-38B2BCEED823Q38682496-D79928A5-825F-4CC9-AD43-DDDF966676E1Q38863355-A6939BAC-09B9-4853-9899-EE63487C81C5Q39467333-C84E7B2E-00D8-485C-A7FE-7A429B3EEE76Q39529499-EC3CB274-0CEB-45BE-B430-E2DA5C7D1A8AQ40215585-9743437A-34C2-44C3-BDBC-83564C5B0DC2Q41653977-7DB3CE42-13A1-4467-B8D5-4C8EDC739859Q43902268-D66CFBDD-592F-4AD7-A381-E1241A562204Q45785775-F47DF4F1-F441-495F-88FB-8AF85FDAABECQ46199971-BEF518F3-F7BF-454F-AD88-A7959F92B913Q48081848-92BBBF15-A385-4BBF-9C7A-17309EA8D0F4Q48145224-E44B5851-07EF-4DEA-BF34-6E867B28C3C1Q50505330-EE5A6274-CEF0-4B04-885E-A5CD07A43050Q50611571-F4712FE5-7FAE-4C1F-99E8-62663EE054E3Q58554211-F34E74BF-7273-415E-A64D-370E5F24BDA8
P2860
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and T
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Clinical outcomes after combin ...... d Combination of Avodart and T
@en
Clinical outcomes after combin ...... d Combination of Avodart and T
@nl
type
label
Clinical outcomes after combin ...... d Combination of Avodart and T
@en
Clinical outcomes after combin ...... d Combination of Avodart and T
@nl
prefLabel
Clinical outcomes after combin ...... d Combination of Avodart and T
@en
Clinical outcomes after combin ...... d Combination of Avodart and T
@nl
P2093
P2860
P1433
P1476
Clinical outcomes after combin ...... d Combination of Avodart and T
@en
P2093
Andrea Tubaro
Betsy B Morrill
Claus G Roehrborn
Jack Barkin
R Paul Gagnier
Timothy H Wilson
P2860
P304
P356
10.1111/J.1464-410X.2011.10124.X
P50
P577
2011-02-18T00:00:00Z